Keros Therapeutics, Inc. (KROS)
11.32
+0.21
(+1.89%)
USD |
NASDAQ |
Sep 04, 16:00
11.31
-0.01
(-0.09%)
After-Hours: 20:00
Keros Therapeutics Research and Development Expense (Quarterly) : 22.33M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 22.33M |
| March 31, 2026 | 16.10M |
| December 31, 2025 | 17.83M |
| September 30, 2025 | 19.52M |
| June 30, 2025 | 43.50M |
| March 31, 2025 | 48.71M |
| December 31, 2024 | 45.63M |
| September 30, 2024 | 49.22M |
| June 30, 2024 | 40.52M |
| March 31, 2024 | 38.26M |
| December 31, 2023 | 37.49M |
| September 30, 2023 | 34.14M |
| June 30, 2023 | 32.53M |
| March 31, 2023 | 31.09M |
| December 31, 2022 | 31.95M |
| Date | Value |
|---|---|
| September 30, 2022 | 21.04M |
| June 30, 2022 | 23.28M |
| March 31, 2022 | 18.08M |
| December 31, 2021 | 18.83M |
| September 30, 2021 | 14.83M |
| June 30, 2021 | 9.983M |
| March 31, 2021 | 11.50M |
| December 31, 2020 | 9.674M |
| September 30, 2020 | 8.395M |
| June 30, 2020 | 7.264M |
| March 31, 2020 | 8.527M |
| December 31, 2019 | 4.161M |
| September 30, 2019 | 3.854M |
| June 30, 2019 | 4.497M |
| March 31, 2019 | 4.867M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Incyte Corp. | 497.47M |
| Viking Therapeutics, Inc. | 115.75M |
| Nurix Therapeutics, Inc. | 85.40M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |